ASCO21: AZ seeks to supplant Imbruvica in CLL with new Calquence dataAstraZeneca has thrown down the gauntlet to AbbVie and Johnson & Johnson with new data for Calquence in Share XASCO21: AZ seeks to supplant Imbruvica in CLL with new Calquence datahttps://pharmaphorum.com/news/asco21-az-seeks-to-supplant-imbruvica-in-cll-with-new-calquence-data/
BeiGene’s Brukinsa fails to beat AbbVie/J&J’s Ibrutinib in WMBeiGene’s Brukinsa (zanubrutinib) has failed to outperform its class rival from Johnson & Johnson/AbbVie in the rare white Share XBeiGene’s Brukinsa fails to beat AbbVie/J&J’s Ibrutinib in WMhttps://pharmaphorum.com/news/beigenes-brukinsa-fails-to-beat-abbvie-jjs-ibrutinib-in-wm/
FDA nod for AZ’s Calquence sets up new Imbruvica showdownAbbVie and Johnson & Johnson are facing a challenge to their blockbuster chronic lymphocytic leukaemia drug Imbruvica from Share XFDA nod for AZ’s Calquence sets up new Imbruvica showdownhttps://pharmaphorum.com/news/fda-nod-for-azs-calquence-sets-up-new-imbruvica-showdown/
